Trial Profile
Can Ivabradine Attenuate Post-revascularisation Microcirculatory Dysfunction in Flow Limiting Coronary Artery Disease?
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Angina pectoris; Coronary artery disease
- Focus Pharmacodynamics
- Acronyms MICRO-PCI
- 16 Aug 2018 Status changed to withdrawn prior to enrolment as funding was not yet achieved
- 20 May 2016 Planned number of patients changed from 64 to 75.
- 20 May 2016 Status changed from withdrawn prior to enrolment to suspended.